You sit down at your favorite restaurant, ready to order. The server hands you the menu, and your stomach sinks. You forgot your reading glasses. Again. Your friend across the table leans back as you extend your arm to its absolute limit. Nothing. Resigned, you snap a photo with your phone just to make out the entrees, a quiet acknowledgment that reading glasses have become an unavoidable companion. But what if a single eye drop could change that?
The slow blur no one escapes
Presbyopia affects nearly every adult past age 40. It develops gradually as the lens inside the eye becomes thicker and less flexible with age, losing the ability to focus up close. The surrounding muscle still contracts, but the lens no longer responds to that movement as it once did. As this flexibility declines, near work requires more effort, and fine print becomes harder to see.
The numbers illustrate presbyopia’s scale. As the global population ages, the number of people affected is projected to grow from 1.8 billion in 2015 to about 2.1 billion by 2030, roughly one-quarter of the world's population. The most recent U.S. estimate (based on 2020 census data) indicates that approximately 128 million adults have presbyopia, representing nearly 90% of adults in the U.S. aged 45 and older.
The eye drops coming for your reading glasses
There are four presbyopia eye drops approved only in the United States. The first of its kind received FDA approval in October 2021 and the newest, in January 2026. A fifth has an FDA approval pending later this year.
Together, these drops represent the first major shift in presbyopia management in decades. What has surprised many clinicians is how rapidly presbyopia treatments are entering the market, fueling optimism that there will soon be multiple options for managing the condition.
From glaucoma drug to reading aid: Pilocarpine's 150-year journey
The journey to presbyopia management began in 1875 when German chemists Hardy and Gerrard isolated pilocarpine from Brazilian jaborandi leaves. One year later, the Austrian ophthalmologist Alexander Weber introduced it as a treatment for glaucoma, a group of conditions that damage the optic nerve. Left untreated, glaucoma can cause permanent vision loss.
Weber recognized that pilocarpine could lower elevated pressure inside the eye, a primary risk factor for glaucoma. It worked by contracting the ciliary muscle and constricting the pupil to improve fluid drainage. For many years, it was a standard treatment for glaucoma, although patients had to endure frequent dosing, stinging, headaches and persistent eye redness.
When newer glaucoma medications emerged with fewer side effects, pilocarpine use declined. But researchers observed a striking pattern in patients who continued pilocarpine: their near vision was better than expected for their age. This sparked speculation that pupil constriction itself may provide enhanced near vision. This led to the hypothesis that pilocarpine's effects extended beyond the use doctors had focused on for years.
Harnessing pilocarpine’s power
Pilocarpine works through the pinhole effect, an optical principle long understood by experts in the field.
Thomas Stokkermans, OD, PhD, from University Hospitals of Cleveland, Ohio, who recently co-authored a review on how pupil size affects vision, explains: "Essentially, when the pupil gets smaller, it works like a camera opening that squeezes shut, blocking peripheral light rays and allowing only central rays through. In bright light, this extends the depth of focus and makes reading small print easier. Think of it as squinting without squinting."
Transforming pilocarpine into a presbyopia treatment required solving problems that earlier formulations had created. These mixtures were acidic and stung on instillation (application), required frequent dosing, and used concentrations for glaucoma rather than near vision. Perhaps more significantly, no approval pathway existed for a lifestyle use like reading enhancement.
The breakthrough came when researchers developed a buffering system that eliminated the burning sensation. Additionally, they optimized the concentration to 1.25%, which was ideal for meaningful pupil constriction with fewer side effects. Studies have found that reducing the pupil to about 2 millimeters produces a noticeable improvement in near vision.
This led to the approval of the first presbyopia eye drop in October 2021. The therapy could work within 15 minutes and last up to six to ten hours, transforming a former glaucoma drug into a modern presbyopia treatment. This milestone opened the door for different medications that could potentially last even longer.
Choosing your presbyopia management means making trade-offs
Presbyopia drops aren’t appropriate for everyone. The approach works best for people with mild to moderate presbyopia, especially those who've worn single-vision glasses or needed no correction at all. Individuals with more advanced presbyopia may need additional strategies. While these eye drops can offer short-term, near-vision improvement without glasses, experts note that many people would likely still need to rely on glasses in some capacity.
Drops can differ in their effects on the eye and in how long they last. All drops constrict the pupil to improve near vision. Both pilocarpine-based drops and another eye drop containing the drug aceclidine engage the muscles around the lens to help bring close objects into focus. Another formulation, a combination drop (carbachol and brimonidine tartrate), uses a dual-agent approach. Carbachol constricts the pupil, while brimonidine tartrate helps maintain it, sustaining the pinhole effect for up to eight to 10 hours.
Cost could be another important factor. Because they’re classified as lifestyle treatments, many insurance plans provide limited or no coverage, leaving many patients to pay out of pocket. Doctors can identify the best fit for patients by reviewing their history and examination findings to make an appropriate treatment recommendation.
The first available drop
In October 2021, pilocarpine 1.25% became the first FDA-approved prescription eye drop for presbyopia. The formulation was engineered to adapt to the tear film, aiming to eliminate the stinging that had plagued earlier versions. It marked a turning point in how near vision could be managed: not as a side effect of glaucoma treatment, but as a primary therapeutic goal.
For many people, the drops may work with their daily routine. Studies indicate that the treatment effect can begin within 15 minutes of application and could last six to 10 hours. Many use it once daily, though some might take a second dose three to six hours later, depending on their visual needs. The drops can be stored at room temperature and, once opened, remain stable until their labeled expiration date.
How effective is it?
The studies set early expectations. About one in three adults gained three lines of near vision on an eye chart in the clinical trials. In real-world situations, fewer than 10% of people using placebo drops hit that mark. Many patients may notice the effect within 15 minutes, and it generally lasts for six to 10 hours.
A lower-dose alternative
Approved in October 2023, pilocarpine 0.4% offers a lower-concentration option, about one-third the strength of the original pilocarpine. It’s formulated without preservatives, making it appealing for those concerned about chemical additives or eye sensitivity.
For this lower-dose option, the studies indicate the treatment effect can begin within 20 minutes of instillation and could last up to eight hours. Many patients use it once daily, though some might add a second dose two to three hours later. It comes as single-use vials that must be stored in the refrigerator. Once opened, individual vials can be kept at room temperature and remain stable for 30 days.
How effective is it?
The lower dose formula works similarly to the stronger one, but is considered more pupil-selective. This means it causes the pupil to constrict without affecting focusing ability as much as higher concentrations do. In the clinical trials, roughly half the participants gained three lines of near vision. Many study participants felt the improvement within about 20 minutes, and the effect can last for up to eight hours.
A longer duration option
Approved in July 2025, aceclidine hydrochloride 1.44% is the first aceclidine-based eye drop for presbyopia, offering a different approach from pilocarpine-based options. This therapy provides one of the longest durations of action (up to 10 hours) among currently approved presbyopia drops and is preservative-free.
The dosing differs from other options. Individuals are instructed to instill one drop in each eye, wait 2 minutes, then instill a second drop. Dr. Stokkermans recommends a practical strategy to his patients: Place the first drop, brush your teeth, then place the second drop — a simple way to ensure proper spacing between doses.
The studies indicate the treatment effect can begin within 30 minutes of instillation and could last up to 10 hours with once-daily use. Aceclidine comes as single-use vials stored in the refrigerator until the expiration date. Once removed from refrigeration, vials remain stable at room temperature for 30 days.
How effective is it?
In reviewing the study data, aceclidine was found to improve near vision for up to 10 hours after initial dosing.
The combination approach
Approved in January 2026, a dual-agent eye drop combines two active ingredients, carbachol and brimonidine, that work in sync. Carbachol constricts the pupil, while brimonidine tartrate prevents the iris dilator muscle from counteracting that constriction, allowing the pupil to remain constricted throughout the day.
The studies indicate the treatment effect can begin within 30 minutes of instillation and could last up to 10 hours with once-daily dosing. The combination drop is a preservative-free formulation in single-use vials, stored in the refrigerator until the expiration date. Once removed from refrigeration, vials remain stable at room temperature for 30 days. The drop will likely be available in the second quarter of 2026.
How effective is it?
In the studies, carbachol and brimonidine tartrate combination therapy achieved near-vision improvement of three or more lines over eight hours without compromising distance vision. The drop was well-tolerated over 12 months of monitoring, with no treatment-related serious adverse events observed.
The fine print of seeing better up close
For many people, presbyopia drops can deliver on their promise of sharper near vision and enhanced reading ability. But outcomes may vary. Some experience mild-to-moderate improvement in near vision.
Both the American Academy of Ophthalmology and the American Optometric Association recommend presbyopia drops as a reasonable option, but with the critical caveat that patients must be properly screened and monitored. Before starting treatment, a comprehensive eye exam, including dilation, is essential. It can reveal underlying conditions that might compromise safety or efficacy of the drops, ensuring that the benefits can outweigh the risks for each individual.
What patients may experience
Like any medication, presbyopia drops can offer benefits but also carry potential drawbacks. As expected, side effects have been noted in the safety study data amongst these therapies – specifically headaches, eye irritation, blurry vision and dim vision may occur frequently but are usually temporary in duration.
These treatment options can differ slightly in their side effects. Pilocarpine-based drops may cause brow pain at higher concentrations, while a lower dose may occasionally cause eye soreness. Both formulations can cause systemic effects in some patients, such as increased sweating, tremor or stomach- or breathing-related symptoms.
For aceclidine, the safety study found that participants most commonly experienced eye irritation during instillation, reported by about 20% of trial participants (16% had dim vision, 13% had headaches). The most common side effects of carbachol and brimonidine tartrate combination therapy, as reported by study participants, were headache, temporary eye pain or irritation, and impaired vision.
Since all drops aim to potentially constrict the pupil, patients might report dim vision in low-light settings, making night driving potentially difficult. These effects are temporary, but they can impact how and when individuals may choose to use the drops.
Understanding the risks
A rare but serious concern has emerged from careful post-market monitoring. Each of these presbyopia drops carries a heightened risk of retinal detachment, a separation of the tissue lining the back of the eye. Certain people might face an even higher risk.
Those with pre-existing retinal conditions (e.g. retinal thinning), a history of cataract surgery with an intraocular lens, previous retinal surgeries (treatment of retinal holes, retinal detachment, etc.), myopia or age-related changes in the vitreous (the gel-like substance filling the eye) would be advised to disclose these types of conditions, if known, to their eye doctor during the examination.
Eye doctors can then monitor patients who use a presbyopia eye drop with an appropriate follow-up schedule that may include a dilated eye examination.
About half of retinal detachment cases typically occur within the first two to three months of starting treatment. However, the overall risk remained elevated through the first year of use.
Patients using presbyopia eye drops should watch for warning signs such as flashes, new floaters, or sudden vision changes and get prompt medical care if they occur*. They should also seek immediate attention for signs of a severe allergic reaction, such as hives, difficulty breathing or swelling of the face, lips, tongue or throat.
Life, briefly, without the search for readers
For years, worsening near vision meant reading glasses tucked into every pocket and scattered across bags or desks. Now, a single, carefully timed eye drop may offer a degree of freedom and simplicity of pre-presbyopia vision, if only for a few hours at a time.
Yet presbyopia drops join, rather than replace, established correction options. Glasses remain the most common solution, with hundreds of progressive addition lens (PAL) designs available to suit different needs and lifestyles. Multifocal contact lenses or monovision treatment (one eye is corrected for distance and the other for near) offer additional alternatives, each with advantages and trade-offs. An eye doctor can help determine which approach, or combination of approaches, best matches an individual's needs.
It’s unclear how many people in the U.S. currently use presbyopia drops or what the full impact might be. However, the research pipeline suggests this is just the beginning for these innovative eye drops. Several investigational drugs act only on selected eye muscles, potentially reducing side effects.
Other drops in the pipeline could soften the aging lens to restore some lost flexibility, though long-term evidence is not yet available.
The approved drops can’t promise to undo presbyopia, but together these options signal a quiet reshaping of how to manage and treat this age-related condition. For anyone who has strained to read a label or resorted to a phone camera at dinner, that shift is both meaningful and welcome.
Editors’ note
It’s recommended that if you experience any of the symptoms mentioned in this article, then you should call your doctor to inform them of a potential side effect and/or adverse event. Further, please report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.
